JIANGSU HENGRUI MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.8 CNY | -0.02% |
|
-3.38% | -3.16% |
| 11:50am | Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs | MT |
| 05-21 | Hengrui Pharma Misses US FDA Approval for Cancer Injection | MT |
| Sales 2024 * | 26.51B 3.66B 288B | Sales 2025 * | 29.93B 4.13B 325B | Capitalization | 279B 38.47B 3,023B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.6B 773M 60.73B | Net income 2025 * | 6.55B 905M 71.07B | EV / Sales 2024 * | 9.62 x |
| Net cash position 2024 * | 23.45B 3.24B 255B | Net cash position 2025 * | 27.67B 3.82B 300B | EV / Sales 2025 * | 8.38 x |
| P/E ratio 2024 * |
49.9
x | P/E ratio 2025 * |
42.6
x | Employees | 19,611 |
| Yield 2024 * |
0.44% | Yield 2025 * |
0.5% | Free-Float | 51.22% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.02% | ||
| 1 week | -3.38% | ||
| Current month | -5.11% | ||
| 1 month | +5.09% | ||
| 3 months | +3.74% | ||
| 6 months | -7.94% | ||
| Current year | -3.16% |
1 week
43.42
46.23
1 month
41.8047.87
Current year
35.5149.15
1 year
35.5150.50
3 years
27.0075.46
5 years
27.0097.39
10 years
6.9197.39
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Bin Dai
CEO | Chief Executive Officer | 48 | 30/06/00 |
Jian Jun Liu
DFI | Director of Finance/CFO | 47 | 18/11/21 |
Yu Xu
CMP | Compliance Officer | 32 | 31/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 54 | 31/12/97 |
Hong Bin Dai
CEO | Chief Executive Officer | 48 | 30/06/00 |
Piao Yang Sun
CHM | Chairman | 65 | 28/02/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.18% | 2 M€ | -14.64% | - | |
| 3.73% | 2 M€ | -14.14% | ||
| 1.74% | 1 M€ | -9.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/05/24 | 43.8 | -0.02% | 24,438,320 |
| 20/05/24 | 43.81 | -2.10% | 39,702,260 |
| 17/05/24 | 44.75 | +0.13% | 37,685,540 |
| 16/05/24 | 44.69 | +0.04% | 23,437,700 |
| 15/05/24 | 44.67 | -1.46% | 15,942,890 |
End-of-day quote Shanghai S.E., May 20, 2024
More quotes
Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products:
- anti-tumor drugs (No. 1 Chinese);
- Anesthetic drugs;
- contrast agents: used in medical imaging;
- anti-inflammatory drugs;
- drugs for the treatment of cardiovascular diseases.
Sector
Pharmaceuticals
Calendar
18/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
43.8
CNY
Average target price
57.5
CNY
Spread / Average Target
+31.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.16% | 38.49B | |
| +37.78% | 723B | |
| +31.34% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +16.42% | 244B | |
| -4.58% | 208B | |
| +10.22% | 210B | |
| +9.32% | 169B |
- Stock Market
- Equities
- 600276 Stock
